PARIS & SEATTLE--(BUSINESS WIRE)--CITN is a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center. Network consists of 27 institutions with the goal of making effective immunotherapy agents broadly available for treatment of cancer. Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC) headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions. The selection was announced following the first meeting of investigators from network institutions recently held in Bethesda, Maryland.
